Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.6 CAD 0.78% Market Closed
Market Cap: 119.5m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

Theratechnologies Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Theratechnologies Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Theratechnologies Inc
TSX:TH
Total Equity
-$19.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bright Minds Biosciences Inc
CNSX:DRUG
Total Equity
CA$19.4m
CAGR 3-Years
199%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ESSA Pharma Inc
NASDAQ:EPIX
Total Equity
$124.6m
CAGR 3-Years
-14%
CAGR 5-Years
21%
CAGR 10-Years
51%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Equity
$388m
CAGR 3-Years
9%
CAGR 5-Years
26%
CAGR 10-Years
23%
Covalon Technologies Ltd
XTSX:COV
Total Equity
CA$21.7m
CAGR 3-Years
34%
CAGR 5-Years
16%
CAGR 10-Years
13%
Spectral Medical Inc
TSX:EDT
Total Equity
-CA$31.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
119.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.42 CAD
Undervaluation 60%
Intrinsic Value
Price

See Also

What is Theratechnologies Inc's Total Equity?
Total Equity
-19.7m USD

Based on the financial report for Aug 31, 2024, Theratechnologies Inc's Total Equity amounts to -19.7m USD.

What is Theratechnologies Inc's Total Equity growth rate?
Total Equity CAGR 1Y
53%

Over the last year, the Total Equity growth was 53%.

Back to Top